These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 32112923)
21. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study. Di Bona D; Nettis E; Bilancia M; Ridolo E; Minenna E; Nizi MC; Albanesi M; Caiaffa MF; Macchia L J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2482-2485.e2. PubMed ID: 33677081 [No Abstract] [Full Text] [Related]
22. Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria. Murray C; Ridge K; Conlon N Eur J Dermatol; 2023 Oct; 33(5):561-562. PubMed ID: 38297938 [No Abstract] [Full Text] [Related]
23. Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres. Can PK; Salman A; Hoşgören-Tekin S; Kocatürk E J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e679-e682. PubMed ID: 34013560 [No Abstract] [Full Text] [Related]
24. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study. Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611 [No Abstract] [Full Text] [Related]
25. A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria. Rijavec M; Košnik M; Koren A; Kopač P; Šelb J; Vantur R; Kogovšek Ž; Bizjak M; Bajrović N; Zidarn M; Korošec P Allergy; 2021 Apr; 76(4):1254-1257. PubMed ID: 32876979 [No Abstract] [Full Text] [Related]
26. Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria. Jesenak M; Ciljakova M; Janickova M; Banovcin P J Investig Allergol Clin Immunol; 2019 Apr; 29(2):144-146. PubMed ID: 31017115 [No Abstract] [Full Text] [Related]
28. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254 [No Abstract] [Full Text] [Related]
29. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896 [No Abstract] [Full Text] [Related]
31. Omalizumab re-treatment rates in chronic spontaneous urticaria. Khan S; Sholtysek S Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397 [No Abstract] [Full Text] [Related]
32. Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience. Ensina LF; de Lacerda AE; Machado LM; Camelo-Nunes I; Solé D Ann Allergy Asthma Immunol; 2015 Dec; 115(6):536. PubMed ID: 26653279 [No Abstract] [Full Text] [Related]
33. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab. Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841 [No Abstract] [Full Text] [Related]
34. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria. Maurer M; Kolkhir P; Moñino-Romero S; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668 [No Abstract] [Full Text] [Related]
35. Age and fast initial response predict omalizumab retreatment in chronic urticaria. Meertens MAJ; Luijf T; van Lindonk EAM; Soegiharto R; Assil S; Alizadeh Aghdam M; Kentie PA; Knulst AC; van Doorn MBA; Röckmann H J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3556-3558.e1. PubMed ID: 37517795 [No Abstract] [Full Text] [Related]
36. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab. Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792 [No Abstract] [Full Text] [Related]
37. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis. Karstarli Bakay OS; Kacar N Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106 [No Abstract] [Full Text] [Related]
38. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria? Thiede RM; Fazel M; MacDonald KM; Abraham I Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375 [No Abstract] [Full Text] [Related]